NEW YORK (GenomeWeb) – Cancer Genetics announced today that it has priced a registered direct offering of 3.5 million equity units at $2 apiece, giving the transaction a $7 million value.

Each unit consists of one share of Cancer Genetics' common stock and one warrant to buy an additional share at an exercise price of $2.35. The warrants are exercisable six months after the date of issuance, and expire 18 months after issuance.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.